Decreased T cell apoptosis and T cell recovery during highly active antiretroviral therapy (HAART)

Clinical Immunology

Volumn 97, Issue 1, 2000, Pages 9-20

  Ensoli, Fabrizio ^a   Fiorelli, Valeria ^a   Alario, Cecilia ^a   De Cristofaro, Maria ^a   Santini Muratori, Donatella ^a   Novi, Arianna ^a   Cunsolo, Maria Giovanna ^a   Mazzetta, Francesca ^a   Giovannetti, Antonello ^a   Mollicone, Bianca ^a   Pinter, Elena ^a   Aiuti, Fernando ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; HAART; Immune reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; LYMPHOCYTE SURFACE MARKER; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MALE; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

EID: 0033799890     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4915     Document Type: Article

References (64)

1. AIDS pathogenesis: A dynamic interaction between HIV and the immune system
2. Direct and indirect mechanisms mediating apoptosis during HIV infection: Contribution to in vivo CD4 T cell depletion
3. Programmed death of T cells in HIV- 1 infection
4. + T cells, modulated by cytokines and effected by lymphotoxin
5. + T cells from human immunodeficiency virus-infected asymptomatic individuals
6. + T cells from human immunodeficiency virus-infected persons: Differential in vitro preventive effect of cytokines and protease antagonists
7. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes
8. Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes
9. Immunophenotypic analysis of peripheral blood mononuclear cells undergoing in vitro apoptosis after isolation from human immunodeficiency virus-infected children
10. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden
11. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection
12. Susceptibility of peripheral blood mononuclear cells to apoptosis is correlated to plasma HIV load
13. Programmed cell death in peripheral lymphocytes from HIV-infected persons: Increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression
14. Apoptosis-related mortality in vitro of mononuclear cells from patients with HIV infection correlates with disease severity and progression
15. + cells during human immunodeficiency virus type 1 infection - Correlation with clinical progression, viral load, and loss of humoral immunity
16. + antigen-specific T cells to undergo apoptosis by HIV-infected monocytes: A two-step mechanism involving the gp 120 molecule
17. + T cells is mediated by macrophages through interaction of HIV gp 120 with chemokine receptor CXCR4
18. Dual role of HIV Tat in regulation of apoptosis in T cells
19. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120
20. Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase- 8
21. TNF-alpha mediated apoptosis of CD4 positive T-lymphocytes: A model of T-cell depletion in HIV infected individuals
22. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes
23. Altered cytokine production and accessory cell function after HIV-1 infection
24. + T cells during an immune response to HIV-1-pulsed dendritic cells
25. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
26. + T cell homeostasis and function in advanced HIV disease
27. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
28. Long-term evaluation of T cell subsets and T cell function after highly active antiretroviral therapy in advanced stage of HIV-1 disease
29. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans
30. Apoptosis and the CD95 system in HIV disease: Impact of highly active anti-retroviral therapy (HAART)
31. Detection and characterization of apoptotic peripheral blood lymphocytes in HIV-1 infection and cancer chemotherapy by a novel flow immunocytometric method
32. Detection of low HIV-1 RNA levels in plasma
33. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: Enhanced sensitivity
34. Inflammatory cytokines and HIV-1-associated neurodegeneration: Oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons
35. Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: Implications for differential CD 45 expression in T cell memory formation
36. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selection on T cells during the virgin to memory cell transition
37. + T-cell memory, CD45R subsets and the persistence of antigen - A unifying concept
38. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome
39. + T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects
40. + T cell population with memory rather than naive cells
41. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy
42. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy
43. Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection
44. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: Differential ligation constantly induces apoptosis
45. + lymphocyte depletion and human immunodeficiency virus replication
46. In vivo analysis of Fas/FasL interactions in HIV-infected patients
47. Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children
48. Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease
49. Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA)
50. Recovery of haematopoietic abnormalities in HIV-1 infected patients treated with HAART
51. Clinical and immunological response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
52. An inhibitor of HIV-1 protease modulates proteosome activity, antigen presentation, and T cell responses
53. + T cell clones
54. - alpha beta T cells
55. + human T cell clones
56. - peripheral T cell line with helper function for B lymphocytes
57. - thymocytes bearing either alpha beta or gamma delta T cell receptors
58. - T cells associated with abnormal Fas expression and hypereosinophilia
59. + T cells
60. Hyper IgE syndrome induced by HIV infection
61. Contact dermatitis in subjects infected with HIV type 1
62. Characterization of rash with indinavir in a national patient cohort
63. Hypersensitivity reactions to drugs in HIV-infected patients: Allergic evaluation and desensitization
64. Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2